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Abstract
Background: Uncertainty remains about the potential harmful effects of antihypertensive therapy
on the developing fetus, especially for beta-blockers (β b).
Methods: We prospectively enrolled all singleton women with a blood pressure ≥  140/90 mm Hg
during pregnancy. The main analysis included 1948 women with all forms of hypertension and
compared the use of β b drugs, non-β b drugs or a combination of both, to no treatment. The
primary study outcome was a composite of the diseases of prematurity, need for assisted
ventilation for greater than 1 day, or perinatal death. A sub-group analysis evaluated the four
treatment options among 583 singleton women with chronic hypertension before 20 weeks
gestation.
Results: In the main analysis, no association was observed between β b use and the primary
composite outcome [adjusted odds ratio (OR) 1.4, 95% CI 0.9–2.2], while an association was seen
with non-β b therapy (OR 5.0, 95% CI 2.6–9.6) and combination therapy (OR 2.9, 95% CI 1.8–4.7).
In the sub-group of 583 women with hypertension before 20 weeks, use of a non-β b drug (OR 4.9,
95% CI 1.7–14.2) or combination therapy (OR 2.9. 95% CI 1.1–7.7) was significantly associated with
the primary composite outcome, while β b monotherapy was not (OR 1.4, 95% CI 0.6–3.4).
Conclusions: Maternal use of antihypertensive medications other than β bs was associated with
both major perinatal morbidity and mortality, while β b monotherapy was not. The combined use
of  β b and non-β b medications demonstrated the strongest association. Before definitive
conclusions can be drawn, a large multicentre randomized controlled trial is needed to address the
issues of both maternal efficacy and fetal safety with the use of one or more antihypertensive agents
in pregnancy.
Background
The effects of maternal antihypertensive drug use during
pregnancy on fetal growth and well being remain uncer-
tain [1]. Meta-analyses of randomized clinical trials have
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highlighted the possible association between antihyper-
tensive therapy and both intrauterine growth restriction
(IUGR) and small for gestational age birthweight (SGA)
[2], especially with the use of beta-blockers (β b) [3].
Pooling data from these clinical trials is questionable,
however, because of large differences in design, patient
characteristics and the various therapies studied [4].
When the results of clinical trials were systematically an-
alyzed on an individual basis, without pooling, there was
no evidence for fetal harm or growth restriction with β b
use [5], with the exception of one small trial [6].
Despite the availability of level I evidence, knowledge
about the effects of β b and other antihypertensive drugs
on perinatal health remains limited. For example, few
studies have evaluated the use of multiple drug therapy
in pregnancy, especially within a routine clinical practice
setting. Second, previous studies that compared β b with
other antihypertensive agents typically enrolled fewer
than 100 women, thereby lacking adequate statistical
power to address rare but important adverse perinatal
events, including perinatal mortality [5]. Accordingly, we
undertook a study of the association between antihyper-
tensive drug use in pregnancy and the risk of major peri-
natal events, while controlling for other important
determinants of perinatal well-being. Our primary goal
was to examine whether β bs were associated with higher
perinatal morbidity and mortality compared to either no
therapy or use of non-β b antihypertensive agents.
Methods
Data collection
We conducted a cohort study from January 1986 to De-
cember 1995. We prospectively enrolled all pregnant
women whose sitting systolic blood pressure was ≥  140
mm Hg or whose diastolic pressure was ≥  90 mm Hg. All
participants were originally seen through the Obstetrics
Service at the McMaster University Medical Center, ei-
ther on an outpatient or inpatient basis. The patients
were consecutively recruited before delivery, and ac-
counted for approximately 98 percent of all hypertensive
pregnant women who delivered at our hospital. McMas-
ter University Medical Centre is a major referral center
for high-risk obstetrics patients and has a level III nurs-
ery.
Each participant's hospital identification number was re-
corded at the time of presentation, and mother and in-
fant data were subsequently abstracted from their
hospital charts by two authors (R.B. and E.B.) three
months after the patient's date of confinement. The
three-month delay allowed for the recording of complete
information on early infant outcomes. Data were record-
ed using a standard data collection form and entered into
a computer database (SPSS, SPSS Inc, Chicago, IL).
The four types of hypertension in pregnancy were classi-
fied according to the taxonomy and definitions of the
1990 National High Blood Pressure Education Program
Working Group [7]. Hence, women with de novo preg-
nancy-acquired hypertension were sub-divided into
those with gestational hypertension or preeclampsia,
while those with chronic hypertension (i.e., hypertension
before 20 weeks gestation) were separated into those
with or without superimposed preeclampsia. The devel-
opment of preeclampsia was defined by hypertension in
association with the presence of at least 2+ proteinuria
or 300 mg of urinary protein per 24-hour specimen col-
lection [7].
Antihypertensive drug use
Antihypertensive drug use was defined as the receipt of
at least one dose of that agent, regardless of the route of
administration, dose or duration of use, gestational age
at initiation, or type or degree of hypertension. Informa-
tion on the drug dose or its duration of use was not re-
corded. Antihypertensive agents were classified as β bs
(i.e., atenolol, propranolol, metoprolol, acebutatolol or
labetolol), non-β b drugs (i.e., nifedipine, methyldopa,
hydralazine, captopril, enalapril, furosemide or hydro-
chlorothiazide), or combined/multiple concomitant
therapy (i.e., β b plus non-β b drug). Magnesium sulphate
was not considered to be an antihypertensive drug.
Although no formal standard for the use of antihyperten-
sive therapy in pregnancy was in effect at McMaster Uni-
versity, there was a general consensus among the
attending Obstetricians and Perinatologists. Therapy
was typically administered to women whose BP was
greater than 140/90 mm Hg in the presence of proteinu-
ria, headache, or symptoms suggestive of preeclampsia,
and at a BP greater than 150/95 mm Hg in the absence of
any symptoms.
Perinatal outcomes
The primary study outcome was the composite of either
a disease of prematurity (i.e., necrotizing enterocolitis,
periventricular hemorrhage and/or hyaline membrane
disease), need for assisted ventilation for greater than 1
day, and/or perinatal death after 20 weeks gestation and
up to 30 days after birth [8,9]. Secondary outcomes in-
cluded SGA, defined as a birthweight below the 10th cen-
tile for gestational age [10,11]; preterm birth before 32 or
37 weeks gestation [12,13]; development of one or more
diseases of prematurity; need for mechanical ventilation
for greater than 1 day [11]; perinatal death; or admission
to the neonatal intensive care unit (NICU) [14,15].
Statistical analysis
In the main analysis, the association between antihyper-
tensive drug use (i.e., β b drugs, non-β b drugs, or a com-BMC Pregnancy and Childbirth 2001, 1:6 http://www.biomedcentral.com/1471-2393/1/6
bination of both) was compared to non-use as the
referent for each study outcome. Using multiple logistic
regression analysis, estimates of the odds ratio were ad-
justed for maternal age, parity, pre-pregnancy weight (by
quartiles), history of delivery before 34 weeks, history of
hypertension in a previous pregnancy, cigarette smok-
ing, pre-pregnancy diabetes mellitus, pre-pregnancy re-
nal dysfunction, use of prednisone, receipt of
betamethasone for fetal lung maturity (not included in
the analyses of SGA and preterm delivery), and gesta-
tional age at which blood pressure (BP) first increased
above 140 mm Hg systolic or 90 mm Hg diastolic.
To evaluate the effect of a potentially longer duration of
drug use, we conducted a subgroup analysis of women
with hypertension before 20 weeks gestation, using the
same exposure variables as in the main analysis. Individ-
ual study outcomes included the primary composite out-
come of perinatal morbidity and mortality, SGA, and
preterm birth before 32 and 37 weeks gestation. We ad-
justed for the variables included in the main analysis, in
addition to the presence of preeclampsia, but no longer
controlled for the gestational age at which the BP first
rose above 140/90 mm Hg. Preeclampsia was included
to account for the possible confounding effect of super-
imposed preeclampsia on preterm birth, SGA or the dis-
eases of prematurity [16].
In the main analysis, baseline maternal characteristics
were compared across groups using either one-way
ANOVA for continuous variables or the chi-square test
for categorical data. All p-values were two-sided, and sig-
nificance was set at a value of 0.05. Statistical analyses
were performed using SAS Version 8 (SAS Institute Inc.,
Cary, North Carolina). The McMaster University Medical
Ethics Committee was consulted at the commencement
of the study in 1986. The committee determined that for-
mal consent was not required because all maternal and
newborn personal identifiers were omitted during data
entry, which preserved patient anonymity and prevented
future patient contact.
Results
During the study period, there were 21 723 births at Mc-
Master University Medical Centre. A total of 1948 single-
ton hypertensive pregnancies (9 percent) were studied,
of which of 864 women (44.4 percent) had gestational
hypertension, 459 (23.6 percent) isolated chronic hyper-
tension, 501 (25.7 percent) isolated preeclampsia, and
124 (6.4 percent) had chronic hypertension with super-
imposed preeclampsia. Selected baseline characteristics
are shown in Table 1.
The various therapies used among all hypertensive wom-
en, as well as those with chronic hypertension, are shown
in Table 2. Approximately half of all women did not re-
ceive an antihypertensive drug, while the remainder re-
ceived either monotherapy (29.2%) or multiple drugs
(20.5%). Of the 968 women with any form of hyperten-
sion who also received active drug therapy, 783 (80.9%)
were on at least a β b and 631 (65.2%) on a non-β b. Aten-
olol comprised over 90% of all β b drug use, and labetolol
less than 5% (Table 2). Of the non-β b drugs, short- or
long-acting nifedipine was used most frequently among
all hypertensive women (39%) as well as those with
chronic hypertension (48%), followed by methyldopa
(28% and 38%, respectively) and hydralazine (13% and
20%, respectively).
Main analysis of women with all forms of hypertension
Compared to women who received no antihypertensive
treatment, use of β bs was not associated with an in-
creased risk for the primary composite outcome (rate
30.9%; OR 1.4, 95% CI 0.9–2.2), while both non-β b ther-
apy (rate 56.7%; OR 5.0, 95% CI 2.6–9.6) and multiple
therapy (rate 59.2%; OR 2.9, 95% CI 1.8–4.7) were (Ta-
ble 3). Similar associations were observed for the diseas-
es of prematurity and the need for neonatal ventilation
for more than 24 hours (Table 3). Admission to the NICU
was significantly more likely among the offspring of
mothers who received β b (OR 2.4, 95% CI 1.6–3.5), and
was even more pronounced in the non-β b (OR 9.9, 95%
CI 4.7–21.0) and multiple therapy (OR 19.2, 95% CI
10.9–30.4) groups. Compared with the rate of 1.9% in
the reference (non-treatment) group, β b use was not as-
sociated with an significantly elevated rate of perinatal
death (rate 3.7%; OR 1.5, 95% CI 0.6–3.4), while non-β b
therapy (rate 5.8%; OR 2.6, 95% CI 1.1–6.3) and combi-
nation therapy (rate 7.1%; OR 3.1, 95% CI 1.4–6.8) were
(Table 3).
A higher risk for SGA was observed among the offspring
of women who received a β b agent (OR 2.3, 95% CI 1.3–
3.4), a non-β b agent (OR 2.1, 95% CI 1.3–3.4), or both
(OR 2.7, 95% CI 1.8–3.9) (Table 4). The rate of preterm
delivery before 32 weeks was also higher with β b use
than with no active treatment (14.7% versus 1.9%, re-
spectively; OR 7.6, 95% CI 4.1–14.1), rising to 20.7% with
non-β b therapies (OR 13.4, 95% CI 6.8–26.2) and to
34.7% with combined therapy (OR 21.1, 95% CI 11.6–
38.3). Similar associations were seen for preterm deliv-
ery before 37 weeks (β b group: OR 5.1, 95% CI 3.8–6.9;
non-β b group: OR 10.3, 95% CI 7.0–15.3); combination
therapy: OR 41.2, 95% CI 27.7–61.2) (Table 4).
Subgroup analysis of women with chronic hypertension
There were 583 women with hypertension before 20
weeks gestation (Table 5). Both non-β b (OR 4.9, 95% CI
1.7–14.2) and combined antihypertensive therapy (OR
2.9. 95% CI 1.1–7.7) were significantly associated withBMC Pregnancy and Childbirth 2001, 1:6 http://www.biomedcentral.com/1471-2393/1/6
Table 1: Baseline characteristics of women with various forms of hypertension during singleton pregnancies
Characteristic No anti-
hyperten-
sive drug 
(n = 980)
β -blocker 
drug 
(n = 428)
Non-β -
blocker drug 
(n = 188)
β -blocker 
and non-β -
blocker drug 
(n = 352)
Statistical 
comparison 
across groups
Maternal age (yr)
Mean (SD) 29.5 (4.9) 29.8 (4.9) 29.2 (5.8) 28.8 (5.6) p = 0.04
No. (%)
< 20 22 (2.3) 10 (2.3) 8 (4.3) 20 (5.7)
20–35 845 (86.2) 366 (85.5) 146 (77.6) 288 (81.8)
> 35 113 (11.5) 52 (12.2) 34 (18.1) 44 (12.5)
No. (%) primigravidae 448 (45.7) 175 (40.9) 83 (44.2) 125 (35.5) p = 0.008
No. (%) with prior preterm delivery before 34 weeks* 50 (12.8) 33 (20.9) 16 (21.1) 29 (27.4) p = 0.002
No. (%) with pre-pregnancy diabetes mellitus 42 (4.3) 14 (3.3) 16 (8.5) 6 (1.7) p = 0.001
No. (%) with renal dysfunction 34 (3.5) 25 (6.0) 22 (11.8) 22 (6.4) p < 0.0001
No (%) smokers 96 (9.8) 38 (9.1) 17 (9.1) 37 (10.8) p = 0.9
Mean (SD) pre-pregnancy weight, kg 71.7 (16.4) 71.3 (16.6) 71.2 (18.5) 69.4 (15.9) p = 0.2
No. (%) according to hypertension type
Gestational hypertension 627 (64.0) 165 (38.6) 33 (17.6) 39 (11.1) p < 0.001
Chronic hypertension 229 (23.4) 122 (28.5) 58 (30.9) 50 (14.2) p < 0.001
Chronic hypertension plus superimposed preeclampsia 18 (1.8) 22 (5.1) 25 (13.3) 59 (16.8) p < 0.001
Isolated preeclampsia 106 (10.8) 119 (27.8) 72 (38.3) 204 (58.0) p < 0.001
*Excludes all primigravidae
Table 2: Antihypertensive therapy among singleton pregnant women with either all forms of hypertension or hypertension before 20 
weeks gestation
No. (%)
Drug use Women with all forms of hypertension 
(n = 1948)
Women with hypertension before 20 
weeks gestation (n = 583)
By number of drugs
None 980 (50.3) 247 (42.4)
Single agent 569 (29.2) 207 (35.5)
Multiple agents 399 (20.5) 129 (22.1)
Total 1948 (100.0) 583 (100.0)
By drug class
i) Beta-blockers*
Atenolol 743 (94.9) 236 (92.9)
Labetolol 29 (3.7) 10 (3.9)
Propranolol 8 (1.0) 6 (2.4)
Acebutalol 3 (0.4) 2 (0.8)
Total 783 (100.0) 254 (100.0)
ii) Non-beta-blockers*
Nifedipine 301 (47.7) 93 (38.9)
Methyldopa 175 (27.7) 91 (38.1)
Hydralazine 129 (20.4) 30 (12.6)
Enalapril or captopril 19 (3.0) 19 (7.9)
Hydrochlorothiazide 5 (0.8) 5 (2.1)
Furosemide 2 (0.3) 1 (0.4)
Total 631 (100.0) 239 (100.0)
*Represents use of that agent either alone or in combination with one or more drugs.BMC Pregnancy and Childbirth 2001, 1:6 http://www.biomedcentral.com/1471-2393/1/6
the primary composite outcome, while use of a β b alone
was not (OR 1.4, 95% CI 0.6–3.4). Compared to no treat-
ment, isolated β b use was associated with both SGA (OR
2.3, 95% CI 1.1–4.5) and preterm delivery before 32 (OR
4.0, 95% 1.3–12.4) or 37 weeks (OR 4.0, 95% CI 2.3–6.9)
(Table 5). A significant relationship was also seen for
combined therapy, with an even higher risk for preterm
birth before 37 weeks (OR 18.9, 95% CI 9.6–37.3). Final-
ly, although treatment with a non-β b drug was not asso-
ciated with SGA (OR 1.3, 95% CI 0.5–3.4) or preterm
birth before 32 weeks (OR 2.0, 95% CI 0.5–7.4), it was
associated with preterm delivery before 37 weeks (OR
4.2, 95% CI 2.2–8.1) (Table 5).
Discussion
In a large prospective cohort of women with hyperten-
sion during pregnancy, maternal use of antihypertensive
medications other than β bs was associated with both ma-
jor perinatal morbidity and mortality, while β b use was
not. The greatest risks for adverse perinatal outcomes
were related to the combined use of β b and non-β b med-
ications. All forms of antihypertensive therapy were as-
sociated with a higher risk for SGA, preterm birth and
admission to the NICU, and multiple therapy had the
strongest association with these events. Similar relation-
ships were evident in the sub-group of women with
chronic hypertension during pregnancy, except that use
of a non-β b drug was not associated with SGA or preterm
birth before 32 weeks.
Several study limitations should caution the reader from
drawing definitive conclusions about the impact of anti-
hypertensive therapy on perinatal outcome. First, we did
not obtain information on drug dose, duration of use or
route of administration. Thus, this study provides no in-
formation about the existence of a dose-response rela-
tionship between drug use and adverse perinatal events.
Because this was not a randomized clinical trial, bias due
to confounding by indication was likely present, in that
women with milder forms of hypertension may have re-
ceived lower doses of oral therapy (e.g., atenolol), while
those with more severe hypertension were probably pre-
scribed a higher dose of an intravenous medication (e.g.,
hydralazine). However, we do know that because the
most commonly used agents in this study – atenolol,
nifedipine and methyldopa – were not available intrave-
nously, their use probably extended beyond the acute
management of severe maternal hypertension with im-
pending delivery. Similarly, although we did not discrim-
inate between the types of β b prescribed in our study
sample, or between the various types of non-β b drugs, we
may assume that most of these relationships are reflec-
tive of the use of atenolol, nifedipine and methyldopa.
Table 3: Rate and adjusted odds ratios (OR) for adverse perinatal outcomes among the offspring of women with any form of hyperten-
sion, according to type of antihypertensive therapy received during pregnancy
Individual outcomes
Primary composite 
outcome*
Diseases of 
prematurity$
Ventilation > 1 day Neonatal intensive 
care unit admission
Perinatal death
Type of 
antihypertensive 
therapy
Rate 
(%)**
Adjusted 
OR 
(95% CI)#
Rate 
(%)
Adjusted
OR 
(95% CI)
Rate 
(%)
Adjusted 
OR 
(95% CI)
Rate 
(%)
Adjusted 
OR 
(95% CI)
Rate 
(%)
Adjusted
OR 
(95% CI)
None 19.5 1.0 15.1 1.0 3.4 1.0 27.4 1.0 1.9 1.0
β -blocker 30.9 1.4 
(0.9–2.2)
26.2 1.4 
(0.9–9.2)
10.9 2.3 
(0.9–5.9)
48.7 2.4 
(1.6–3.5)
3.7 1.5 
(0.6–3.4)
Non-β -blocker 56.7 5.0 
(2.6–9.6)
49.1 4.4 
(2.1–9.2)
24.6 6.9 
(2.3–20.6)
77.2 9.9
 (4.7–21.0)
5.8 2.6 
(1.1–6.3)
Both β -blocker and 
non-β -blocker
59.2 2.9 
(1.8–4.7)
55.6 2.8
 (1.7–4.8)
31.0 3.7 
(1.4–9.4)
87.4 18.2 
(10.9–30.4)
7.1 3.1 
(1.4–6.8)
*Defined as a composite of either hyaline membrane disease (HMD), necrotizing enterocolitis (NEC), periventricular hemorrhage (PVH), assisted 
ventilation > 1 day, or perinatal death after 20 weeks gestation and up to 30 days after birth. **Represents the rate for each perinatal outcome 
according to type of antihypertensive therapy $Includes HMD, NEC and/or PVH. #All odds ratios were adjusted for maternal age, parity, pre-preg-
nancy weight, history of delivery before 34 weeks, history of hypertension in a previous pregnancy, cigarette smoking, pre-pregnancy diabetes mel-
litus, pre-pregnancy renal dysfunction, use of prednisone, receipt of betamethasone for fetal lung maturity, and gestational age at which blood 
pressure first increased above 140/90 mm Hg.BMC Pregnancy and Childbirth 2001, 1:6 http://www.biomedcentral.com/1471-2393/1/6
β b medications are contraindicated in individuals with
specific diseases like asthma, a common condition whose
presence in pregnancy has been associated with an in-
creased risk for preeclampsia, preterm delivery and SGA
[17]. Accordingly, absence of β b use may have been con-
founded by the presence of other diseases like asthma,
which could explain the relatively lower degree of perina-
tal morbidity with β b therapy compared to non-β b treat-
ments. Similarly, there may have been a lower threshold
for induction of labor or Cesarean delivery among wom-
en who were referred to our center for the management
of more complex or severe maternal hypertension or fe-
tal disease. Thus, because these data may be biased, and
their internal and external validity questioned, they may
not be applicable to some women with stable, mild and
asymptomatic hypertension.
Two Cochrane Collaboration systematic reviews have ex-
amined the use of β bs [3] as well as all types of medica-
tion [18] for the treatment of pregnant women with mild
to moderate hypertension. In the first review, compris-
ing 14 randomized trials of oral β bs versus placebo or no
therapy [3], β bs decreased the risk of progression to se-
vere hypertension (relative risk [RR] 0.37, 95% CI 0.26–
0.53) and the need for additional antihypertensive drugs
(RR 0.44, 95% CI 0.31–0.62) [3]. However, there was in-
sufficient data to draw conclusions about the effect on
perinatal mortality or preterm delivery, but β bs were
minimally associated with SGA (RR 1.34, 95% CI 1.01–
1.79). Among 11 trials, β bs appeared to be both equally
effective and as safe as methyldopa [3]. In the second re-
view, comparing antihypertensive drugs with placebo or
no treatment, active therapy reduced the risk of severe
hypertension (24 trials; RR 0.52, 95% CI 0.41–0.64), but
not preeclampsia (19 trials; RR 0.99, 95% CI 0.84–1.18),
perinatal death (23 trials; RR 0.71, 0.46–1.09), preterm
birth (12 trials; RR 0.98, 95% CI 0.85–1.13), or SGA (17
trials; RR 1.13, 0.91–1.42) [18]. Thus, within a heteroge-
neous group of randomized trials [5], treatment of mild
to moderate hypertension, whether in the form of β bs or
other drugs, remains controversial.
The advantage of a large, prospective study like MOS
HIP 2 is its ability to examine several important "hard"
perinatal outcomes, and to generate estimates of effect
size with statistical certainty. MOS HIP 2 provided infor-
mation on perinatal outcomes within the realm of clini-
cal practice, and included a broad array of women with
different mechanisms and degrees of hypertension. By
adjusting for multiple potential confounders, such as the
gestational age at which the BP rose, we may have re-
duced the likelihood that antihypertensive drug use was
merely a marker of both the acuity and degree of hyper-
tension and, accordingly, the associated risk of preterm
delivery and neonatal prematurity. Similarly, by limiting
our sub-group analysis to women with chronic hyperten-
sion, we increased the likelihood that maternal exposure
to antihypertensive therapy would be of longer duration.
In doing so, there remained no relationship between β b
use and the primary endpoint of major perinatal disease
or death, an association that was observed for both non-
β b and combination drug therapy.
The debate about whether β b drugs [3,5] or antihyper-
tensive treatment in general [2,18] may cause IUGR nei-
ther begins nor ends with the current study. Even
Table 4: Rate and adjusted odds ratios (OR) for small for gestational age birthweight (SGA) and preterm birth among the offspring of 
women with any form of hypertension, according to type of antihypertensive therapy received during pregnancy
Preterm birth
SGA Before 32 weeks Before 37 weeks
Type of anti-hypertensive 
therapy
Rate 
(%)*
Adjusted OR
 (95% CI)**
Rate (%) Adjusted OR 
(95% CI)
Rate (%) Adjusted OR 
(95% CI)
None 9.0 1.0 1.9 1.0 12.2 1.0
β -blocker 19.9 2.3 (1.6–3.3) 14.7 7.6 (4.1–14.1) 45.3 5.1 (3.8–6.9)
Non-β -blocker 20.7 2.1 (1.3–3.4) 20.7 13.4 (6.8–26.2) 62.2 10.3 (7.0–15.3)
Both β -blocker and non-β -blocker 28.5 2.7 (1.8–3.9) 34.7 21.1 (11.6–38.3) 87.5 41.2 (27.7–61.2)
*Represents the rate for each perinatal outcome according to type of antihypertensive therapy **All odds ratios were adjusted for maternal age, 
parity, pre-pregnancy weight, history of delivery before 34 weeks, history of hypertension in a previous pregnancy, cigarette smoking, pre-preg-
nancy diabetes mellitus, pre-pregnancy renal dysfunction, use of prednisone, and gestational age at which blood pressure first increased above 140/
90 mm Hg.BMC Pregnancy and Childbirth 2001, 1:6 http://www.biomedcentral.com/1471-2393/1/6
randomized clinical trials [2,3,5] of active therapy are bi-
ased by the presence of co-intervention, cross-over, con-
tamination and drop-outs. For example, in a well-
publicized clinical trial by Butters et al., 33 women with
mild primary hypertension were randomized to atenolol
or placebo at approximately 16 weeks gestation [6]. In-
fants of mothers assigned atenolol weighed an average of
910 g less than those in the placebo group, but four wom-
en in the placebo group withdrew from the study. A sec-
ond trial compared atenolol with placebo for the
treatment of mild gestational hypertension during the
third trimester, with no difference in birthweight be-
tween groups; however, data were reported on only 85 of
120 women (70.8%) randomized [19]. A recent clinical
trial randomized 56 asymptomatic women with an in-
creased cardiac output before 24 weeks gestation to ei-
ther atenolol or placebo [20]. For the primary outcome
of preeclampsia, the relative risk was 0.3 (95% CI 0.07–
1.4) in favor of atenolol, and only in the small sub-group
of nulliparous women was treatment with atenolol sig-
nificantly associated with a 440 g mean lower mean
birthweight (p = 0.02). Thus, although it is possible that
atenolol may cause some degree of growth restriction,
this has not been demonstrated when the drug is com-
pared to another form of active treatment [3], or in the
presence of more severe hypertension, when maternal
benefit may be greater. Finally, no class effect has been
demonstrated for β bs in general [4].
It may not be surprising that the risk of preterm delivery
in our study was significantly associated with the use of
antihypertensive therapy, since the initiation of therapy
might simply reflect the onset of either new or worsening
hypertension and the need for delivery. However, it is
possible that β bs possess tocophilic properties that could
predispose a woman to preterm labor. At least two place-
bo-controlled clinical trials have used intravenous β bs in
the management of dysfunctional labor, reporting lower
rates of Caesarian delivery with active treatment [21,22].
The relative degree of association observed in this study
was substantially lower with β b than non-β b antihyper-
tensive drugs, for delivery before 32 (OR 7.6 versus OR
13.4 among all women, respectively) or 37 weeks (OR 5.1
versus OR 10.3, respectively).
Combined antihypertensive therapy was a strong marker
for preterm birth and a moderate indicator of SGA. In-
terestingly, however, the associated risk for other serious
perinatal outcomes, such as the primary composite out-
come, was either less than or similar to that for mono-
therapy with a non-β b drug (Tables 3 and 5). Further
research might investigate whether there are differences
in placental blood flow and fetal growth according to
treatment regimen (monotherapy vs. combined antihy-
pertensive therapy).
Although no significant association was seen between β b
use and major perinatal morbidity or mortality, it cannot
Table 5: Rate and adjusted odds ratios (OR) for the primary composite outcome, small for gestational age birthweight (SGA) and pre-
term birth among the offspring of women with chronic hypertension, according to type of antihypertensive therapy received during 
pregnancy
Preterm birth
Primary composite 
outcome*
SGA Before 32 weeks Before 37 weeks
Type of antihyper-
tensive therapy
Rate (%) Adjusted OR 
(95% CI)#
Rate 
(%)
Adjusted OR 
(95% CI)
Rate (%) Adjusted OR 
(95% CI)
Rate 
(%)
Adjusted OR 
(95% CI)
None 12.9 1.0 7.3 1.0 2.0 1.0 12.2 1.0
β -blocker 26.1 1.4 (0.6–3.4) 18.8 2.3 (1.1–4.5) 10.4 4.0 (1.3–12.4) 39.6 4.0 (2.3–6.9)
Non-β -blocker 48.8 4.9 (1.7–14.2) 14.5 1.3 (0.5–3.4) 12.0 2.0 (0.5–7.4) 48.2 4.2 (2.2–8.1)
Both β -blocker and non-
β -blocker
53.7 2.9 (1.1–7.7) 26.6 2.9 (1.3–6.3) 26.6 5.3 (1.7–16.3) 80.7 18.9 (9.6–37.3)
*Defined as a composite of either hyaline membrane disease, necrotizing enterocolitis, periventricular hemorrhage, assisted ventilation > 1 day, or 
perinatal death after 20 weeks gestation and up to 30 days after birth. #All odds ratios were adjusted for maternal age, parity, pre-pregnancy weight, 
history of delivery before 34 weeks, history of hypertension in a previous pregnancy, cigarette smoking, pre-pregnancy diabetes mellitus, pre-preg-
nancy renal dysfunction, development of proteinuria, use of prednisone, receipt of betamethasone for fetal lung maturity (which is excluded for the 
analysis of SGA and preterm delivery), and the presence of ≥  2+ proteinuria or 300 mg of urinary protein per 24-hour specimen.BMC Pregnancy and Childbirth 2001, 1:6 http://www.biomedcentral.com/1471-2393/1/6
be inferred that they are "safer" for the fetus. Rather, as-
suming that the current study was both valid and ade-
quately powered to evaluate major perinatal outcomes,
we may conclude that either 1) β bs are prescribed for ma-
ternal hypertension when there is less threat to the fetus
or mother, while non-β b drugs are used in isolation or in
combination with β bs when that threat is greater; or 2)
β bs are, in fact, less harmful to the fetus compared to
other antihypertensive drugs. Thus, these findings,
which are hypothesis generating, should be tested by a
study capable of demonstrating causation.
A large international randomized active-control clinical
trial is urgently needed to help resolve the controversy
surrounding the safety and efficacy for mother and child
of treating hypertension during pregnancy. The reasons
for such a large double-masked clinical trial are many
[23], including the fact that the condition is common; the
choices for therapy are few, unlikely to change for several
years and inexpensive; and the time to outcome is less
than 40 weeks. Women with a BP greater than 160/100
mm Hg without evidence of preeclampsia or impending
delivery could be enrolled.
Randomization could be stratified according to the pres-
ence of hypertension before versus after 20 weeks gesta-
tion, and treatment might compare a β b to a
dihydropyridine calcium channel blocker or methyl-
dopa, for example. Maternal outcomes should include
mode of delivery [21,22], progression to preeclampsia or
eclampsia [20], and drug side effects [5], while perinatal
outcomes should encompass those included in the cur-
rent study.
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